Cellphire, Inc. announced today that it had closed on a private funding round totaling approximately $1.3 million. The funding came from undisclosed investors and is expected to augment the $69 million commitment to Cellphire by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services. The use of proceeds of the funding is expected to be for the development of therapeutic applications outside of the company’s work for BARDA.
Contacts:
Media
Sharon Burns
Director, Communications
sburns@cellphire.com
Investor Relations
Tom Dann
Chief Investment Officer
tdann@cellphire.com